Sandoz Group AG Posts Strong FY 2024 Results, Eyes Continued Growth in 2025
Sandoz Group AG has delivered a robust financial performance for the full year 2024, with net sales surging by a substantial percentage. The company’s sales momentum was driven by double-digit growth in biosimilars, which benefited from recent launches and a strong base-business performance. This impressive growth was further underscored by a moderate increase in operating income and a substantial improvement in the core EBITDA margin.
The company’s biosimilars segment has been a key driver of growth, with recent launches and a robust base-business performance contributing to double-digit sales growth. This segment’s success has been a key factor in the company’s overall financial performance, and it is expected to continue to be a major contributor to growth in the coming year.
Guidance for FY 2025
Looking ahead to the full year 2025, Sandoz has provided guidance that suggests the company is poised for continued growth. The company is expecting mid-single digit net-sales growth, which would represent a continuation of the strong sales momentum seen in 2024. Additionally, the company is targeting a higher core EBITDA margin, which would further improve profitability and drive long-term growth.
A Growth Trajectory
Sandoz has demonstrated a clear commitment to growth and expansion, and the company’s financial performance in 2024 is a testament to this strategy. With a strong biosimilars segment and a robust base-business performance, the company is well-positioned to continue its growth trajectory in the coming year. As the company looks to the future, investors and analysts will be watching closely to see how Sandoz executes on its growth strategy and delivers on its guidance for 2025.
Key Highlights
- Net sales growth of a substantial percentage in FY 2024
- Double-digit growth in biosimilars segment
- Moderate increase in operating income
- Substantial improvement in core EBITDA margin
- Guidance for mid-single digit net-sales growth in FY 2025
- Targeting a higher core EBITDA margin in FY 2025